| Efficacy and safety of ranibizumab 0.5 mg in Chinese patients with visual impairment due to diabetic macular edema: results from the 12-month REFINE study | |
| Li, Xiaoxin; Dai, Hong; Li, Xiaorong; Han, Mei; Li, Jun; Suhner, Andrea; Lin, Renxin; Wolf, Sebastian; Qi, Huijun; Tao, Ye | |
| 2019 | |
| 卷号 | 257期号:3页码:529-541 |
| 关键词 | Anti-vascular endothelial growth factor Diabetic macular edema Pro re nata Ranibizumab |
| ISSN号 | 0721-832X |
| DOI | 10.1007/s00417-018-04213-x |
| URL标识 | 查看原文 |
| 收录类别 | SCIE |
| 内容类型 | 期刊论文 |
| URI标识 | http://www.corc.org.cn/handle/1471x/6343652 |
| 专题 | 中国医学科学院 北京协和医学院 |
| 推荐引用方式 GB/T 7714 | Li, Xiaoxin,Dai, Hong,Li, Xiaorong,et al. Efficacy and safety of ranibizumab 0.5 mg in Chinese patients with visual impairment due to diabetic macular edema: results from the 12-month REFINE study[J],2019,257(3):529-541. |
| APA | Li, Xiaoxin.,Dai, Hong.,Li, Xiaorong.,Han, Mei.,Li, Jun.,...&Dong, Wenjia.(2019).Efficacy and safety of ranibizumab 0.5 mg in Chinese patients with visual impairment due to diabetic macular edema: results from the 12-month REFINE study.,257(3),529-541. |
| MLA | Li, Xiaoxin,et al."Efficacy and safety of ranibizumab 0.5 mg in Chinese patients with visual impairment due to diabetic macular edema: results from the 12-month REFINE study".257.3(2019):529-541. |
| 个性服务 |
| 查看访问统计 |
| 相关权益政策 |
| 暂无数据 |
| 收藏/分享 |
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。
修改评论